Hepatitis C Management in Special Populations

  • Author: Mark S. Sulkowski, MD (More Info)
  • Editor In Chief: Stefan Zeuzem, MD
  • Last Reviewed: 8/17/18 (What's New)

Summary

  • AASLD/IDSA guidance panel recommends highly active DAA regimens as preferred therapy for genotype 2-6 HCV infection in HCV/HIV-coinfected patients (Management Guidelines)[AASLD-IDSA HCV]
  • EASL guidance panel recommends highly active DAA regimens for genotype 2-6 HCV infection in HCV/HIV coinfected patients (Management Guidelines)[EASL HCV]

Action required

Keywords: Hepatitis C, Hepatitis C-Special Populations, Hepatitis C-Sustained Virologic Response, Hepatitis C-Treatment

©2020 Clinical Care Options, LLC. All Rights Reserved.

The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.